PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma
Ryan J. Duchatel(Hunter Medical Research Institute), Matthew D. Dun(Hunter Medical Research Institute), Izac J. Findlay(Hunter Medical Research Institute), Susan Hua(University of Newcastle Australia), Mika L. Persson(Hunter Medical Research Institute), Ron Firestein(Unknown), Javad Nazarian(University Children's Hospital Zurich), Paul Daniel(Brigham and Women's Hospital), Sandra Laternser(University Children's Hospital Zurich), Maria Tsoli(Cancer Institute of New South Wales), Murray J. Cairns(Hunter Medical Research Institute), Dilana E. Staudt(Hunter Medical Research Institute), Elizabeth E. Manning(University of Pittsburgh), Abdul Mannan(Jeju National University), Claire Sun(Hudson Institute of Medical Research), Mohd Fairuz(Hudson Institute of Medical Research), Nicholas A. Vitanza(Seattle Children's Hospital), Frank Alvaro(Hunter Medical Research Institute), David S. Ziegler(Cancer Institute of New South Wales), Eric H. Raabe(Johns Hopkins University), Christopher L. Tinkle(St. Jude Children's Research Hospital), M. Fairuz B. Jamaluddin(University of Newcastle Australia), Alicia M. Douglas(Hunter Medical Research Institute), Tyrone S. Beitaki(Hunter Medical Research Institute), Jason E. Cain(Monash Medical Centre), Brett Nixon(Hunter Medical Research Institute), David D. Eisenstat(Royal Children's Hospital), Zacary P. Germon(Hunter Medical Research Institute), Nicole M. Verrills(Hunter Medical Research Institute), Padraic S. Kearney(Hunter Medical Research Institute), Heather C. Murray(Hunter Medical Research Institute), David A. Skerrett‐Byrne(Helmholtz Zentrum München), Sabine Mueller(University of California, San Francisco), Sarah Parackal(Monash University), Christopher V. Dayas(Hunter Medical Research Institute), Dylan Kiltschewskij(Hunter Medical Research Institute), Evangeline R. Jackson(Hunter Medical Research Institute), Valdes-Mora Fatima(Cancer Institute of New South Wales), Carl Koschmann(University of Michigan)
Cited by 1
Related Papers
Advances and Challenges of Liposome Assisted Drug Delivery
|Frontiers in Pharmacology|2015|2.5k
Current Trends and Challenges in the Clinical Translation of Nanoparticulate Nanomedicines: Pathways for Translational Development and Commercialization
|Frontiers in Pharmacology|2018|937
Comprehensive Analysis of Hypermutation in Human Cancer
|Cell|2017|795
Functionally defined therapeutic targets in diffuse intrinsic pontine glioma
|Nature Medicine|2015|711